|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 12, 2014 ) Dallas, TX -- Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family Flaviviridae and genus hepacivirus. It has a positive-sense, single-stranded RNA molecule enveloped by a lipid bilayer. Hepatitis C can lead to acute infection or chronic infection. Nearly 80 percent of the infected individuals suffering from acute infection are asymptomatic. Symptoms manifested in the rest include nausea, dark urine, fever, anorexia, gray-colored faces, abdominal pain, and joint pain. Nearly 20 percent of infected individuals develop jaundice, which is characterized by the yellowing of skin and eyes. Nearly 15-45 percent of acutely infected individuals recover from the infection spontaneously within the first six months of infection. This happens because the immune system mediated the clearance of the virus from the body. The remaining 55-85 percent of infected individuals who fail to clear the virus within six months develop chronic hepatitis C phase. Chronic infection can lead to mild-to-moderate symptoms or chronic symptoms such as liver fibrosis, liver cirrhosis, and hepatic cancer. The World Health Organization (WHO) estimates that globally, 130-150 million people suffer from chronic hepatitis B. It also reported that every year 350,000-500,000 infected individuals die because of hepatitis C-related hepatic disorders. Currently, there is no vaccine for the prevention of hepatitis C infection; however, various treatment options for hepatitis C infection are available.
Analysts forecast the Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Hepatitis C market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through sales of various drugs administered to treat chronic hepatitis caused by genotype 1-6 of hepatitis C virus.
This report, the Global Hepatitis C Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Hepatitis C market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=209324 .
Key Regions
Americas
APAC
EMEA
Key Vendors
F. Hoffmann-La Roche
Gilead Sciences
Johnson & Johnson
Merck
Vertex Pharmaceuticals
Other Prominent Vendors
Abbvie
Achillion Pharmaceuticals
Bristol-Myers Squibb
Mitsubishi Tanabe Pharma
Novartis
Market Driver
Increase in Injection Drug Users
For a full, detailed list, view our report
Market Challenge
Side-effects of Current Therapy
For a full, detailed list, view our report
Market Trend
Emergence of Interferon-free Therapies
For a full, detailed list, view our report
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Single User License is US $3000 for Discount Inquire@ http://www.rnrmarketresearch.com/contacts/discount?rname=209324 .
About us:Rnrmarketresearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
